Phase II Study of RC1416 Injection in COPD

NCT07402551 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: RC1416
DRUG: RC1416 Placebo

Sponsor

Nanjing RegeneCore Biotech Co., Ltd.